The FDA Approves J&J, Bayer's Xarelto

Introduction

On Monday, Oct.14, Johnson & Johnson's (J&J) subsidiary Janssen Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) approved Xarelto (rivaroxaban) for the prevention of blood clots in acutely ill patients without a high risk of bleeding during and after hospitalization.

Xarelto is an anticoagulant manufactured by Bayer and jointly marketed by Janssen Pharmaceuticals. Including the latest approval, Xarelto now has eight indications, six of which are specifically for the treatment, prevention, and reduction in the risk of recurrence of blood clotting.

Xarelto has been allegedly linked to causing uncontrollable bleeding, which leads to unexpected serious injuries and even death. Xarelto lawsuits are consolidated under the federal multidistrict litigation (MDL No.2592; In Re: Xarelto (Rivaroxaban) Products Liability Litigation) in the Eastern District of Louisiana.

Comments

Walgreens Settles Federal Opioid Case for $300 Million

Categories: Opioids

Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.

The U.S. Department of Justice announced on Monday…

Study: Opioid Use in Pregnancy May Shrink Newborn Brains

Categories: Opioids

New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…

Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting

Categories: Opioids

The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…

The FDA Approves J&J, Bayer's Xarelto